Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABS), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.
SAB Biotherapeutics, Inc. (Nasdaq: SABS), or SAB BIO, generates frequent news as a clinical-stage biopharmaceutical company advancing fully human immunoglobulin G (hIgG) and human anti-thymocyte immunoglobulin (hATG) therapies for immune and autoimmune disorders. Most recent headlines focus on SAB-142, the company’s multi-specific, fully human anti-thymocyte globulin in development as a potentially disease-modifying, redosable immunotherapy for autoimmune type 1 diabetes (T1D) in new-onset, Stage 3 patients.
News updates commonly cover clinical milestones for SAB-142, including Phase 1 trial results and the launch and progress of the Phase 2b registrational SAFEGUARD study. Releases describe safety, pharmacodynamic, and immunogenicity findings, such as the absence of serum sickness and anti-drug antibodies in the Phase 1 trial, as well as the design and enrollment status of the SAFEGUARD trial at multiple centers around the world.
SABS news also highlights SAB BIO’s scientific presence at major medical meetings. The company regularly announces oral and poster presentations at conferences such as the European Association for the Study of Diabetes (EASD), the International Society for Pediatric and Adolescent Diabetes (ISPAD), and the Asian Conference on Innovative Therapies for Diabetes Management. These items detail new data on SAB-142’s mechanism of action, immunomodulatory effects without sustained lymphodepletion, and pharmacokinetic profiling.
Investors and observers will also find corporate and investor-relations updates, including participation in healthcare investor conferences and changes to the Board of Directors, as well as summaries of quarterly financial results and business highlights. For anyone tracking SABS, this news feed provides an ongoing view into SAB BIO’s clinical development progress, scientific communications, governance developments, and key events related to its lead program SAB-142 and its broader human IgG platform.
SAB BIO (Nasdaq: SABS) has provided an update on its SAB-142 clinical trial at the European Association for the Study of Diabetes Annual Meeting. The company has completed Phase 1 enrollment of all planned cohorts in healthy volunteers and is now enrolling patients with type 1 diabetes in the last cohort. Notably, the target dose of 2.5mg/kg was completed with no observation of serum sickness.
SAB-142, a first-in-class human anti-thymocyte immunoglobulin, is being developed to delay the onset and progression of type 1 diabetes. The Phase 1 trial aims to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. The company remains on track for a topline Phase 1 data readout by the end of the year.
SAB BIO (Nasdaq: SABS), a clinical-stage biopharmaceutical company, has announced its participation in the European Association for the Study of Diabetes 60th Annual Meeting on September 9, 2024, in Madrid. The company's Executive Vice President and Chief Medical Officer, Alexandra Kropotova, MD, MBA, will present on the topic 'Protecting pancreatic beta cells with multi-target, multi-epitope immunotherapy: SAB-142'.
SAB BIO is developing a novel immunotherapy platform using human anti-thymocyte immunoglobulin (hIgG) to delay the onset or progression of type 1 diabetes (T1D). The presentation will take place during the INNODIA EASD Symposium at 8:45 am in the Beijing Hall of the EASD Symposium, highlighting the company's innovative approach to T1D treatment.
SAB BIO (Nasdaq: SABS) reported its Q2 2024 financial results and provided company updates. Key highlights include:
1. FDA clearance for SAB-142 IND application
2. Appointment of Lucy To as CFO
3. Founding of a new Clinical Advisory Board
4. Cash position of $37.3 million as of June 30, 2024
5. R&D expenses increased to $6.8 million in Q2 2024
6. Net loss of $7.3 million for Q2 2024
The company reaffirmed its cash runway into 2026 and remains focused on developing SAB-142 for delaying or stopping the progression of type 1 diabetes. SAB-142 is on track for a topline Phase 1 data readout by year-end.
SAB Biotherapeutics (Nasdaq: SABS) has announced the formation of a clinical advisory board to guide the development of SAB-142, their leading therapeutic candidate for type 1 diabetes (T1D). The board comprises world-leading experts in T1D therapies and will provide strategic direction, insights on clinical protocols, and support research initiatives. SAB-142 is a human anti-thymocyte immunoglobulin (hIgG) designed to delay the onset or progression of T1D.
Samuel J. Reich, Chairman and CEO of SAB BIO, emphasized the potential of SAB-142 to be a best-in-class human antibody treatment for safe, reliable life-long dosing, potentially delaying clinical onset and progression of T1D. The advisory board includes prominent experts from institutions such as Cardiff University, University of Florida, University of California, University of Melbourne, and Katholieke Universiteit Leuven.
SAB Biotherapeutics (Nasdaq: SABS) has appointed Lucy To as Chief Financial Officer, effective August 12, 2024. With over 18 years of investment banking and strategic operational expertise, Ms. To will lead corporate finance, strategy, and strategic business relationships at SAB. The company is developing human anti-thymocyte immunoglobulin (hIgG) to delay the onset or progression of type 1 diabetes (T1D).
SAB's CEO, Samuel J. Reich, expressed confidence in Ms. To's ability to contribute to the company's upcoming milestones for SAB-142, their lead candidate. Ms. To, previously a Managing Director in the Healthcare Investment Banking Group at Wells Fargo, brings extensive experience in M&A, IPOs, and other equity and debt financings in the healthcare sector, with transactions totaling over $50 billion.
SAB Biotherapeutics, now rebranded as SAB BIO, has announced a new name, logo, and website updates. Despite the cosmetic changes, the company's stock symbol remains SABS. This rebranding aligns with SAB BIO's mission to address immune and autoimmune disorders, specifically type 1 diabetes (T1D), using their unique immunotherapy platform. CEO Samuel J. Reich emphasized the importance of this transformation in representing SAB BIO's focus on developing therapies to slow disease progression in T1D patients. The announcement comes ahead of their presentation at the American Diabetes Association 84th Scientific Sessions in Orlando. Additionally, the company reiterated its financial outlook for 2024 and upcoming milestones, including a Phase 1 study data readout for their lead candidate, SAB-142.
SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company, will present at the American Diabetes Association (ADA) 84th Scientific Sessions from June 21-24, 2024, in Orlando, Florida. The presentation will focus on SAB's novel immunotherapy platform, specifically its human anti-thymocyte immunoglobulin (hIgG) aimed at delaying the onset or progression of type 1 diabetes (T1D). Eric Sandhurst, Ph.D., SAB's Senior Program Manager, will present a poster on June 23, 2024, from 12:30 PM to 1:30 PM, detailing the IND-Enabling Assessment of Tolerance and Safety for SAB-142, a first-in-class fully human anti-thymocyte immunoglobulin. The poster will also be published online in the journal Diabetes® and available for viewing throughout the ADA sessions.
SAB Biotherapeutics (Nasdaq: SABS) announced the departure of its Chief Financial Officer, Michael King, effective June 4, 2024. King is leaving to become CEO at a privately-held oncology company but will continue as an advisor to SAB until the end of the year. The company has initiated a search for his permanent replacement. In the interim, Mark Conley, Vice President of Finance, will serve as Interim CFO. SAB remains optimistic about its future, focusing on expanding its clinical programs, including the delay or progression of type 1 diabetes with its hIgG therapy. The company confirmed its 2024 financial outlook and upcoming milestones, including a Phase 1 data readout for SAB-142.
SAB Biotherapeutics (Nasdaq: SABS) announced that the FDA has cleared its IND application for SAB-142, a type 1 diabetes therapy, to proceed to a Phase 1 clinical trial in the US.
SAB-142, a human anti-thymocyte immunoglobulin (hIgG), aims to delay the onset or progression of type 1 diabetes. The ongoing HUMAN trial will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SAB-142 in both healthy volunteers and participants with type 1 diabetes.
The HUMAN trial is a randomized, double-blind, placebo-controlled, single-ascending dose study, with doses ranging from 0.03mg/kg to 2.5mg/kg. The trial design mimics the MELD-ATG study, whose topline results are expected in 2025.
The third cohort has been fully enrolled and dosed without observed serum sickness. This clearance marks a significant advancement in SAB's mission to slow disease progression in type 1 diabetes patients.
SAB Biotherapeutics (Nasdaq: SABS) announced its Q1 2024 financial results and company updates. The company highlighted its focus on T1D immunotherapy, with significant progress in its SAB-142 program. Key pipeline milestones include the complete enrollment of the third cohort in its Phase 1 trial with no serum sickness observed and an impactful partnership with INNODIA. Financially, SAB reported a net loss of $4.0 million, a marked improvement from the $7.4 million loss in the previous year. Operating expenses increased, driven by higher R&D and G&A costs, reflecting intensified efforts in T1D research. Cash reserves stand at $45.2 million, anticipated to fund operations into 2026, assuming full exercise of outstanding warrants.
FAQ
What is the current stock price of SAB BIOTHERAPEUTICS (SABS)?
What is the market cap of SAB BIOTHERAPEUTICS (SABS)?
